Healthcare provider profile · identity verified

John G Meisel, MD

Family Practice · WAILUKU, HI · NPI 1003844465

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	793	287
Lisinopril	Lisinopril	291	103
Losartan Potassium	Losartan Potassium	263	102
Amlodipine Besylate	Amlodipine Besylate	261	89
Rosuvastatin Calcium	Rosuvastatin Calcium	178	64
Levothyroxine Sodium	Levothyroxine Sodium	142	49
Metformin Hcl	Metformin Hcl	119	48
Metoprolol Succinate	Metoprolol Succinate	115	42
Gabapentin	Gabapentin	114	37
Tamsulosin Hcl	Tamsulosin Hcl	112	40
Allopurinol	Allopurinol	109	37
Metformin Hcl Er	Metformin Hcl	99	40
Hydrochlorothiazide	Hydrochlorothiazide	95	35
Albuterol Sulfate Hfa	Albuterol Sulfate	87	50
Trazodone Hcl	Trazodone Hcl	79	23
Jardiance	Empagliflozin	72	25
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	69	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	67	23
Atenolol	Atenolol	66	29
Simvastatin	Simvastatin	63	22
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	57	23
Metoprolol Tartrate	Metoprolol Tartrate	57	24
Alvesco	Ciclesonide	53	21
Arexvy	Rsvpref3 Antigen/As01e/Pf	53	53
Furosemide	Furosemide	53	16
Glipizide	Glipizide	49	18
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	48	16
Oxycodone Hcl	Oxycodone Hcl	45	14
Pantoprazole Sodium	Pantoprazole Sodium	43	17
Acyclovir	Acyclovir	42	18
Zolpidem Tartrate	Zolpidem Tartrate	42	15
Clopidogrel	Clopidogrel Bisulfate	41	16
Fluoxetine Hcl	Fluoxetine Hcl	40	suppressed
Baclofen	Baclofen	39	12
Lorazepam	Lorazepam	38	11
Alendronate Sodium	Alendronate Sodium	35	16
Morphine Sulfate Er	Morphine Sulfate	35	suppressed
Tenivac	Tetanus-Diphtheria Toxoids/Pf	34	34
Xarelto	Rivaroxaban	32	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	30	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	29	suppressed
Potassium Chloride	Potassium Chloride	29	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	29	26
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	29	suppressed
Bupropion Xl	Bupropion Hcl	28	suppressed
Ezetimibe	Ezetimibe	28	suppressed
Colchicine	Colchicine	27	13
Glipizide Er	Glipizide	27	11
Pregabalin	Pregabalin	27	suppressed
Warfarin Sodium	Warfarin Sodium	25	suppressed
Carvedilol	Carvedilol	24	suppressed
Celecoxib	Celecoxib	24	suppressed
Tramadol Hcl	Tramadol Hcl	24	suppressed
Buspirone Hcl	Buspirone Hcl	23	suppressed
Citalopram Hbr	Citalopram Hydrobromide	23	suppressed
Montelukast Sodium	Montelukast Sodium	23	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	22	suppressed
Finasteride	Finasteride	22	11
Pravastatin Sodium	Pravastatin Sodium	22	12
Triamcinolone Acetonide	Triamcinolone Acetonide	22	16
Duloxetine Hcl	Duloxetine Hcl	21	suppressed
Terazosin Hcl	Terazosin Hcl	21	suppressed
Testosterone	Testosterone	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Sertraline Hcl	Sertraline Hcl	20	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	20	suppressed
Chlorthalidone	Chlorthalidone	18	11
Prednisone	Prednisone	18	11
Testosterone Cypionate	Testosterone Cypionate	18	suppressed
Spironolactone	Spironolactone	17	suppressed
Ibuprofen	Ibuprofen	16	suppressed
Clobetasol Propionate	Clobetasol Propionate	15	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Azelastine Hcl	Azelastine Hcl	14	suppressed
Diazepam	Diazepam	14	suppressed
Meloxicam	Meloxicam	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Cephalexin	Cephalexin	13	12
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	13	suppressed
Naproxen	Naproxen	13	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Amoxicillin	Amoxicillin	12	suppressed
Armour Thyroid	Thyroid,pork	12	suppressed
Glycopyrrolate	Glycopyrrolate	12	suppressed
Scopolamine	Scopolamine	12	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	11	11
Liraglutide	Liraglutide	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed
Torsemide	Torsemide	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error